Bolode

HomeProductsAxitinib API

Axitinib API

(Total 9 Products)
Axitinib API CAS 319460-85-0

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
Axitinib Impurity O 885126-34-1

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
6- Nitroindazole CAS 7597-18-4

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
Axitinib API CAS 886230-77-9

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
Axitinib API CAS 886230-76-8

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
Axitinib API CAS 886230-75-7

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
3-Iodo-6- nitroindazole cas 70315-70-7

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
6-Iodo-1H- indazole cas 261953-36-0

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
2-mercapto -N-methylbenzamide CAS 20054-45-9

Unit PriceUSD 1 / Gram

Min.Order Unit Price
1 Gram USD 1 / Gram

Packaging: Package as customer's requirements

Supply Ability: in stock

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be...
Home > Products > Axitinib API

China Axitinib API Suppliers

Overview: Axitinib is a multi-targeted small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The currently approved indication for the market is the second-line treatment of advanced renal cancer, which means that axitinib can be selected for advanced renal cancer after the failure of the chemicalbook treatment of Sutent. In addition to renal cancer, this drug has also been tried by patients for liver cancer, sarcoma, neuroendocrine tumors and other solid tumors that are relatively sensitive to anti-angiogenic drugs and have a rich tumor blood supply, and has certain curative effects.

Introduction:Axitinib is a white powder with a melting point of 218.4°C, slightly soluble in polyethylene glycol 400, slightly soluble in methanol or ethanol, very slightly soluble in acetonitrile, and almost insoluble in water. The solubility in pHChemicalbook1.2 hydrochloric acid solution at 20°C is 0.8 mg/ml, and the solubility in pH6.8 phosphate buffer solution is 0.2 μg/ml, which are typical pH-dependent drugs.

Related Products List

Home

Product

Whatsapp

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send